Home > Result Summaries: Compounds > Haemophilus influenzae Type b, Meningococcal C-TT Conjugate Vaccine > Result Summary for 108886

Result Summary for 108886

Result Summary

Protocol ID:	108886
Clinical Study ID:	108886
Official Title:	A Phase IV, single centre, open-label study, to investigate the persistence of antibody 6 years after priming immunization with meningococcal conjugate vaccine and indiction of long term immunological memory by assessing persistence of memory B cells and response to the Hib-MenC (Menitorix) vaccine
Phase:	phase 4
Study Indications or Diseases:	Hib, Meningococcal disease
Generic Name:	Haemophilus influenzae Type b, Meningococcal C-TT Conjugate Vaccine
Trade/Product Name:	Menitorix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Perrett KP et. (2010) Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999–2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis. 50(12):1601–1610. O’Connor D et al. Functional SNPS within TLR3 involve response to serogroup C meningococcal conjugate vaccine. Abstract presented at the 30th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Thessaloniki, Greece, 8-12 May 2012. Pollard AJ et al. (2009) Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nature reviews immunology. 9(3):213-220.